The European Medicines Agency (EMA) said Tuesday that unusual blood clots should be listed as a "very rare" side effects of Johnson & Johnson's coronavirus vaccine, but that the benefits of the shot still outweigh the risks.

Why it matters: The agency's determination of a "possible link" to a rare kind of blood clot comes ahead of an expected ruling by the U.S. FDA this week on whether to lift its pause on the J&J vaccine rollout.

More than 80% of Americans 65 and older have received at least one dose of a coronavirus vaccine, per the CDC, but millions across the country remain unvaccinated — particularly in the South.

Why it matters: Seniors who have yet to receive their shot remain highly vulnerable to the virus even as the country overall becomes safer.

Most Americans support the pause in distribution of the Johnson & Johnson COVID-19 vaccine, and so far there's no evidence that it's leading to broader vaccine hesitancy, according to the latest installment of the Axios/Ipsos Coronavirus Index.

Driving the news: In our weekly national survey, 91% of respondents were aware of the temporary pause recommended by the Food and Drug Administration and the Centers for Disease for Control and Prevention. Of those, 88% said the pause was a responsible decision.

The State Department announced Monday that it will be issuing "do not travel" guidelines for roughly 80% of countries worldwide and urged Americans to "reconsider all travel abroad."

Why it matters: The announcement emphasizes the ongoing severity of the COVID-19 pandemic, despite a ramped up domestic vaccination campaign and many states moving to reopen. Globally, cases continue to surge.

1. Health: Global COVID-19 death toll surpasses 3 million — Telehealth brings moms-to-be improved care.
2. Vaccines: All U.S. adults now eligible for COVID-19 vaccine — CDC says half of U.S. adults have received one COVID-19 vaccine dose — Fauci expects decision on resuming J&J coronavirus vaccine by Friday.
3. Political: Watchdog says agency infighting increased health and safety risks at start of pandemic — When vaccine hesitancy becomes political
4. World: Zimbabwe releases hundreds of prisoners to reduce COVID risk — Head of world's largest vaccine maker urges Biden to lift export ban on raw materials.
5. Food: COVID-19 smell loss leads to culinary experimentation.
6. Variant tracker: Where different strains are spreading.

Management failures among federal agencies contributed to "health and safety risks" as the U.S. tried to return citizens from abroad and quarantine them domestically at the outset of the pandemic, the Government Accountability Office (GAO) said in a report requested by Congress out Monday.

Why it matters: The 13-month investigation revealed that lack of preparation led to infighting at the Health and Human Services Department (HHS) as divisions repeatedly clashed about who should oversee rescue operations, according to the report.

All 50 U.S. states, plus Washington, D.C. and Puerto Rico, have made U.S. adults over the age of 16 eligible for COVID-19 vaccines, successfully meeting the April 19 deadline set by President Biden.

Why it matters: The landmark speaks to the increased pace of the national vaccination campaign, but will increase pressure on the federal government, states and pharmaceutical companies to provide adequate vaccine supply and logistics.

The counties with the most vaccine-hesitant residents generally also voted for Donald Trump in 2020 by large margins, whereas the counties with the lowest levels of hesitancy generally also had fewer Trump voters.

Why it matters: Your politics don't have anything to do with whether you're vulnerable to the coronavirus if you remain unvaccinated.

Half of U.S. adults have received at least one dose of the COVID-19 vaccine and about a third are fully vaccinated, according to new data from the Centers for Disease Control and Prevention.

Why it matters: COVID-19 cases and hospitalizations are still on the rise, CDC director Rochelle Walensky said during Friday's White House COVID-19 briefing. With cases in many states being driven by variants, public health officials have emphasized the need to ramp up vaccinations.

NIAID director Anthony Fauci said he expects a decision on resuming the Johnson & Johnson vaccine by Friday after a CDC panel meets to discuss the issue, he told NBC's Meet the Press.

Why it matters: Acting FDA Commissioner Janet Woodcock said she expected the vaccine's pause to only last "a matter of days," as health officials investigated data on the "extremely rare" blood clots that caused the agency to recommend a halt to J&J vaccinations last week.